The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung

dc.contributor.authorBakır, Kemal
dc.contributor.authorSivrikoz, Muammer Cumhur
dc.contributor.authorErbağcı, Burak
dc.contributor.authorUçak, Ramazan
dc.contributor.authorNurozler, Feza
dc.contributor.authorÜstünsoy, Haşim
dc.contributor.buuauthorŞenkaya, Işık
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Kardiyovasküler Cerrahi Anabilim Dalı.tr_TR
dc.contributor.scopusid15827259500tr_TR
dc.date.accessioned2021-11-30T13:09:25Z
dc.date.available2021-11-30T13:09:25Z
dc.date.issued2002-04
dc.description.abstractIn addition to preventing tissue energy loss during cardiopulmonary bypass. pentoxifylline (Ptx) prevents the production of pro-inflammatory cytokines as well. The aim of this study was to investigate whether Ptx decreases the inflammatory effects of cardiopulmonary bypass on the lungs during open-heart surgery, The patients in the study group (n=15) who were going through an open-heart surgery had 500 mg l(-1) of Ptx added to their prime solution, whereas the patients in the control group (n=10) only received prime solution. Pre-pump and post-pump blood samples were obtained from both groups and assayed for intereukin-6 (IL-6), interleukin-8 (IL-8) and tumour necrosis factor alpha (TNFalpha), Lung tissue samples that were obtained after the pump were examined with light microscopy and stained for tissue TNFalpha Non-parametric Wilcoxon test was utilized for statistical evaluation, In the post-pump period, the difference in the IL-6, IL-8 and TNFalpha levels of the two groups was found to be statistically significant (P < 0.005). The tissue samples from the control group had significant staining with TNFalpha. We think that Ptx has important protective effects on the lungs during cardiopulmonary bypass.tr_TR
dc.identifier.citationÜstünsoy H. vd. (2002). "The inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lung". Respiratory Medicine, 96(4), 275-279.tr_TR
dc.identifier.endpage279tr_TR
dc.identifier.issn0954-6111
dc.identifier.issue4tr_TR
dc.identifier.pubmed12000008tr_TR
dc.identifier.scopus2-s2.0-0036553573tr_TR
dc.identifier.startpage275tr_TR
dc.identifier.urihttps://doi.org/10.1053/rmed.2001.1255
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0954611101912557
dc.identifier.urihttp://hdl.handle.net/11452/22893
dc.identifier.volume96tr_TR
dc.identifier.wos000175123200011tr_TR
dc.indexed.pubmedPubmedtr_TR
dc.indexed.scopusScopustr_TR
dc.indexed.wosSCIEtr_TR
dc.language.isoentr_TR
dc.publisherW B Saunderstr_TR
dc.relation.collaborationYurtiçitr_TR
dc.relation.journalRespiratory Medicinetr_TR
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/openAccesstr_TR
dc.subjectPentoxifyllinetr_TR
dc.subjectLungtr_TR
dc.subjectInflammatory responsetr_TR
dc.subjectCardiopulmonary bypasstr_TR
dc.subjectMyocardial protectiontr_TR
dc.subjectIschemiatr_TR
dc.subjectReperfusiontr_TR
dc.subjectInjurytr_TR
dc.subjectCardiovascular system & cardiologytr_TR
dc.subjectRespiratory systemtr_TR
dc.subject.emtreeAdulttr_TR
dc.subject.emtreeAntiinflammatory activitytr_TR
dc.subject.emtreeArticletr_TR
dc.subject.emtreeBlood pumptr_TR
dc.subject.emtreeBlood samplingtr_TR
dc.subject.emtreeCardiopulmonary bypasstr_TR
dc.subject.emtreeChemoluminescencetr_TR
dc.subject.emtreeClinical articletr_TR
dc.subject.emtreeFemaletr_TR
dc.subject.emtreeClinical trialtr_TR
dc.subject.emtreeControlled clinical trialtr_TR
dc.subject.emtreeControlled studytr_TR
dc.subject.emtreeDrug mechanismtr_TR
dc.subject.emtreeHumantr_TR
dc.subject.emtreeHeart ventricle septum defecttr_TR
dc.subject.emtreeHistologytr_TR
dc.subject.emtreeHuman tissuetr_TR
dc.subject.emtreeImmunoassaytr_TR
dc.subject.emtreeMaletr_TR
dc.subject.emtreeLung biopsytr_TR
dc.subject.emtreeOpen heart surgerytr_TR
dc.subject.emtreePneumoniatr_TR
dc.subject.emtreePriority journaltr_TR
dc.subject.emtreeRank sum testtr_TR
dc.subject.emtreeStatistical significancetr_TR
dc.subject.emtreeValvular heart diseasetr_TR
dc.subject.emtreeAntibiotic agenttr_TR
dc.subject.emtreeBicarbonatetr_TR
dc.subject.emtreeCorticosteroidtr_TR
dc.subject.emtreeCytokinetr_TR
dc.subject.emtreeİnterleukin 6tr_TR
dc.subject.emtreeInterleukin 8tr_TR
dc.subject.emtreeMannitoltr_TR
dc.subject.emtreePentoxifyllinetr_TR
dc.subject.emtreeRinger lactate solutiontr_TR
dc.subject.emtreeTumor necrosis factor alphatr_TR
dc.subject.scopusPentoxifylline; Methylxanthine; Phosphodiesterase Inhibitorstr_TR
dc.subject.wosCardiac & cardiovascular systemstr_TR
dc.subject.wosRespiratory systemtr_TR
dc.titleThe inhibition of pro-inflammatory cytokines with pentoxifylline in the cardiopulmunary bypass lungtr_TR
dc.typeArticle
dc.wos.quartileQ2 (Cardiac & cardiovascular systems)tr_TR
dc.wos.quartileQ3 (Respiratory system)tr_TR

Files

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
Şenkaya_vd_2002.pdf
Size:
236.52 KB
Format:
Adobe Portable Document Format
Description:

License bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:

Collections